We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

85 hedge funds and large institutions have $137M invested in UroGen Pharma in 2023 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 10

31% more funds holding

Funds holding: 65 → 85 (+20)

18% more capital invested

Capital invested by funds: $116M → $137M (+$20.7M)

2.92% more ownership

Funds ownership: 53.41% → 56.33% (+2.9%)

25% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 20

36% less call options, than puts

Call options by funds: $193K | Put options by funds: $300K

Holders
85
Holders Change
+20
Holders Change %
+30.77%
% of All Funds
1.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
15
Reduced
20
Closed
10
Calls
$193K
Puts
$300K
Net Calls
-$107K
Net Calls Change
-$876K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$8.97M
2
State Street
State Street
Massachusetts
+$3.3M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.07M
4
Northern Trust
Northern Trust
Illinois
+$1.74M
5
AA
AlphaCentric Advisors
Puerto Rico
+$1.68M

Top Sellers

Rank Fund Capital Flow
1
MMH
Menora Mivtachim Holdings
Israel
-$4.29M
2
SCM
Stonepine Capital Management
Oregon
-$2.79M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.06M
4
Millennium Management
Millennium Management
New York
-$1.79M
5
Bank of America
Bank of America
North Carolina
-$1.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
First Manhattan
76
First Manhattan
New York
$10.3K – – –
TRCT
77
Tower Research Capital (TRC)
New York
$7.29K -$11.8K -1,074 -60%
Osaic Holdings
78
Osaic Holdings
Arizona
$6.42K – – –
Fidelity Investments
79
Fidelity Investments
Massachusetts
$5.21K +$541 +49 +11%
CG
80
Cutler Group
California
$4K +$4.41K +400 New
CUAMC
81
China Universal Asset Management Company
China
$3.18K -$66 -6 -2%
Russell Investments Group
82
Russell Investments Group
United Kingdom
$2.62K – – –
CCP
83
Carmel Capital Partners
California
$2.07K +$2.21K +200 New
QCG
84
Quadrant Capital Group
Ohio
$580 – – –
HF
85
HRT Financial
New York
– -$560K -60,623 Closed
Qube Research & Technologies (QRT)
86
Qube Research & Technologies (QRT)
United Kingdom
– -$427K -46,213 Closed
GPP
87
Great Point Partners
Connecticut
– -$362K -39,222 Closed
6CM
88
683 Capital Management
New York
– -$176K -19,000 Closed
LP
89
LMR Partners
United Kingdom
– -$127K -13,746 Closed
BFM
90
Boothbay Fund Management
New York
– -$121K -13,075 Closed
OC
91
Oppenheimer & Co
New York
– -$95.2K -10,301 Closed
Lazard Asset Management
92
Lazard Asset Management
New York
– -$28K -3,111 Closed
QC
93
Quent Capital
New York
– -$795 -86 Closed
EI
94
Ellevest Inc
New York
– -$397 -43 Closed
1 2 3
4

URGN Hedge Fund Activity: Q2 2023 in Review

85 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2023, worth a combined $137M — up 18% from $116M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new URGN positions and 10 closed out — a net gain of 20 holders — while 15 added to existing stakes and 20 trimmed.

The largest buyer was BlackRock, adding an estimated $8.97M. The largest seller was Menora Mivtachim Holdings, cutting an estimated $4.29M.

  • 85 institutional investors held UroGen Pharma (URGN) as of Q2 2023, up from 65 in Q1 2023.
  • Funds reported $137M of UroGen Pharma stock for Q2 2023, up 18% quarter-over-quarter.
  • 30 funds opened new UroGen Pharma positions in Q2 2023 and 10 closed out, a net change of +20 holders.
  • The largest UroGen Pharma buyer in Q2 2023 was BlackRock, an estimated $8.97M added.
  • The largest UroGen Pharma seller in Q2 2023 was Menora Mivtachim Holdings, an estimated $4.29M sold.

Based on aggregated 13F filings for Q2 2023.